(Corrects day of the week to Thursday)
ZURICH, July 18 Actelion, Europe's
largest biotech company lifted its full-year guidance on
Thursday and now expects to return to growth in 2013 boosted by
strong sales of its mainstay product and benefits from its
Actelion said it now expects core earnings to cross into the
double-digit percentage range for 2013. Due to the faster growth
in 2012 and 2013, Actelion forecast stable earnings in 2014 and
growth in at least the single-digit range in 2015.
It had previously forecast stable core earnings in 2013 in
local currencies, followed by a return to growth in 2014 and
double digit percentage growth in 2015.
Sales of its main product Tracleer, a treatment for
pulmonary arterial hypertension (PAH) rose 2 percent to 766.9
million Swiss francs ($812.5 million) in the first half, while
net profit for the period was 199.5 million francs.
($1 = 0.9439 Swiss francs)
(Reporting by Caroline Copley)